Galapagos NV

Galapagos NV, incorporated in 1999, is a biotechnology company headquartered in Mechelen, Belgium. The company's business is primarily concentrated on the discovery and development of small molecule medicines that feature novel modes of action. The sectors that constitute their main business activities are drug discovery, clinical development, and the commercialization of therapies, with a particular focus on inflammation, fibrosis, and various other medical indications. The company's brand is not reflected in the form of typical consumer products but is closely associated with its research pipeline and pharmaceutical developments. One of its most significant products is filgotinib, developed in partnership with Gilead Sciences, which is targeted at treating conditions like rheumatoid arthritis, among others. While Galapagos NV conducts research and development on a global scale, the actual market for its products and services is contingent upon the commercial reach and regulatory approvals obtained by its collaborative partners. This primarily includes various countries in Europe and North America, along with other international markets where these partner entities, such as Gilead Sciences, are operational. (Powered by AI)